A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary) ; Trastuzumab-deruxtecan (Primary) ; Volrustomig (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms DL03
- Sponsors AstraZeneca
- 03 Sep 2024 According to an AstraZeneca media release, at WCLC 2024, an oral presentation will highlight efficacy and safety data from Part 1 of the DESTINY-Lung03 Phase Ib trial.
- 27 Aug 2024 Planned number of patients changed from 248 to 244.
- 05 Jun 2024 Planned number of patients changed from 168 to 248.